- Open
- 7.25
- High
- 7.30
- Low
- 7.05
- Close
- 7.25
- Change
- -0.25 (-3.45%)
- Volume
- 102,220
⌘K
| 7 Jan 2026 | 07:00:07 | Secondary Trading Following Cancellation |
| 7 Jan 2026 | 07:00:01 | Cancellation - Tissue Regenix Group Plc |
| 22 Dec 2025 | 16:08:04 | Result of General Meeting and Cancellation |
| 17 Dec 2025 | 18:00:00 | Tissue Regenix Group |
| 8 Dec 2025 | 07:00:11 | Update re. proposed cancellation of shares |
| 2 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 3 Apr 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 28 Mar 2023 | Annual Report and Accounts (to 2022-12-31) |
| 23 Sept 2024 | Maiden pre-tax profit | |
| 10 Apr 2024 | Six consecutive periods of >20% growth | |
| 18 Sept 2023 | Continuation of the positive momentum | |
| 5 Apr 2023 | Turning profitable and cash-generative | |
| 27 Sept 2022 | Operating leverage | |
| 19 Jul 2022 | Strong 1H’22 sales suggest upside potential | |
| 19 Apr 2022 | On pathway to sustainability | |
| 19 Oct 2021 | Faster-than-anticipated recovery |
Tissue Regenix is a prominent player in the regenerative medicine industry, specializing in medical devices. The company has developed a unique decellularization technology that eliminates cellular components, including DNA, from soft tissue obtained from animals and humans, resulting in an acellular tissue.
| 7 Jan 2026 | 07:00:07 | Secondary Trading Following Cancellation |
| 7 Jan 2026 | 07:00:01 | Cancellation - Tissue Regenix Group Plc |
| 22 Dec 2025 | 16:08:04 | Result of General Meeting and Cancellation |
| 17 Dec 2025 | 18:00:00 | Tissue Regenix Group |
| 8 Dec 2025 | 07:00:11 | Update re. proposed cancellation of shares |
| 2 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 3 Apr 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 28 Mar 2023 | Annual Report and Accounts (to 2022-12-31) |
| 23 Sept 2024 | Maiden pre-tax profit | |
| 10 Apr 2024 | Six consecutive periods of >20% growth | |
| 18 Sept 2023 | Continuation of the positive momentum | |
| 5 Apr 2023 | Turning profitable and cash-generative | |
| 27 Sept 2022 | Operating leverage | |
| 19 Jul 2022 | Strong 1H’22 sales suggest upside potential | |
| 19 Apr 2022 | On pathway to sustainability | |
| 19 Oct 2021 | Faster-than-anticipated recovery |
Tissue Regenix is a prominent player in the regenerative medicine industry, specializing in medical devices. The company has developed a unique decellularization technology that eliminates cellular components, including DNA, from soft tissue obtained from animals and humans, resulting in an acellular tissue.
